Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Hill & Smith sees no major hit from tariffs; Trading in line

(Sharecast News) - Infrastructure product supplier Hill & Smith said it was not currently seeing any significant impact from US tariffs, adding that any raw materials cost increases had been offset by price rises. The company on Thursday also said trading in the first four months of the year was in line and it expected to meet full-year consensus earnings estimates. Revenue was 3% higher on a constant currency basis, with further operating margin expansion against a strong prior period comparator.

"With around 95% of our materials being sourced in the US and less than 1% of revenue from US exports, we have low direct exposure to the tariffs announced so far," it added.

"Where raw material cost increases are coming through, our businesses have been able to mitigate this by raising prices. We have not seen any indication of reduced activity levels or delays to projects, supporting our confidence that the structural drivers for US infrastructure growth remain intact."

Trading in the period had been positive and in line with expectations, reflecting continuing robust market demand for infrastructure products in the US and a resilient performance in the UK despite a subdued market backdrop.

Current company-compiled analyst consensus expectations for the full year is for underlying operating profit of £150.3m with a range of £145.4m-£154.0m.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.